| Symbol | SGMT |
|---|---|
| Name | SAGIMET BIOSCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 155 BOVET ROAD,SUITE 303, SAN MATEO, California, 94402, United States |
| Telephone | +1 650 561-8600 |
| Fax | — |
| — | |
| Website | https://www.sagimet.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001400118 |
| Description | Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Additional info from NASDAQ: |
📋 GEORGE KEMBLE (Director) plans to sell 351K shares of SAGIMET BIOSCIENCES INC (at $9.28 each, total $3.3M) Filed: Aug 14, 2026 | ID: 008152
Read moreNew Form SCHEDULE 13G - Sagimet Biosciences Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003438 <b>Size:</b> 15 KB
Read moreSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Read moreKemble George 🟡 adjusted position in 20.2K shares (2 derivative) of Sagimet Biosciences Inc. (SGMT) at $9.95 Transaction Date: Aug 11, 2026 | Filing ID: 347407
Read more📋 GEORGE KEMBLE (Director) plans to sell 20K shares of Sagimet Biosciences Inc. (at $9.57 each, total $193K) Filed: Aug 11, 2026 | ID: 007964
Read more(30% Negative) SAGIMET BIOSCIENCES INC. (SGMT) Reports Q3 2026 Financial Results
Read moreSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Read moreSagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Read moreNew Form SCHEDULE 13G - Sagimet Biosciences Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0002012383-26-003143 <b>Size:</b> 10 KB
Read more📋 GEORGE KEMBLE (Director) plans to sell 19K shares of SAGIMET BIOSCIENCES INC (at $7.82 each, total $147K) Filed: Jul 20, 2026 | ID: 007226
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07216313 | A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Pa… | Phase1 | Healthy | Completed | 2025-09-30 | 2025-10-20 | ClinicalTrials.gov |
| NCT06989840 | Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in H… | Phase1 | Acne | Recruiting | 2025-06-03 | 2027-01-01 | ClinicalTrials.gov |
| NCT06692283 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients W… | Phase3 | MASLD | Withdrawn | 2025-03-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT06594523 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients W… | Phase3 | MASH | Withdrawn | 2025-03-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT05743621 | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Phase1 | Prostatic Neoplasms, Castration-Resistant | Recruiting | 2023-11-20 | 2029-01-25 | ClinicalTrials.gov |
| NCT05835180 | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild… | Phase1 | Non-alcoholic Steatohepatitis | Completed | 2023-05-01 | 2023-12-18 | ClinicalTrials.gov |
| NCT05657834 | Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 … | Phase1 | Healthy Volunteers | Completed | 2022-11-21 | 2022-12-21 | ClinicalTrials.gov |
| NCT04906421 | Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | Phase2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | Completed | 2021-08-12 | 2023-10-02 | ClinicalTrials.gov |
| NCT03808558 | Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | Phase2 | KRAS Gene Mutation | Active_Not_Recruiting | 2019-09-11 | 2026-12-01 | ClinicalTrials.gov |
| NCT03938246 | Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | Phase2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | Completed | 2019-03-22 | 2021-10-02 | ClinicalTrials.gov |
| NCT02948569 | Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects Wit… | Phase1 | Metabolic Syndrome | Completed | 2017-02-01 | 2019-01-30 | ClinicalTrials.gov |
| NCT02223247 | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patient… | Phase1 | Solid Malignant Tumor | Completed | 2013-11-01 | 2017-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| TVB-3567 | Other | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| Placebo | Other | Phase PHASE3 | MASLD | WITHDRAWN | NCT06692283 |
| denifanstat | Other | Phase PHASE3 | MASLD | WITHDRAWN | NCT06692283 |
| TVB-2640 | Other | Phase PHASE1 | Solid Malignant Tumor | COMPLETED | NCT02223247 |
| [14C]-TVB-2640 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05657834 |
| TVB-2640 - 50 mg | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05835180 |
| TVB-2640 75 mg (US) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| Placebo (China) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 50 mg (China) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| Placebo (US) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 50 mg (US) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 25 mg (US) | Other | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| 3-V Bioscience-2640 | Other | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02948569 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | COMPLETED | NCT04906421 |
| TVB-2640 | Other | Phase PHASE2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | COMPLETED | NCT04906421 |
| Placebo | Other | Phase PHASE3 | MASH | WITHDRAWN | NCT06594523 |
| Denifanstat | Other | Phase PHASE3 | MASH | WITHDRAWN | NCT06594523 |
| Enzalutamide | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05743621 |
| TVB-2640 | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05743621 |
| TVB-2640 | Other | Phase PHASE2 | KRAS Gene Mutation | ACTIVE_NOT_RECRUITING | NCT03808558 |
| Resmetirom | Other | Phase PHASE1 | Healthy | COMPLETED | NCT07216313 |
| Denifanstat | Other | Phase PHASE1 | Healthy | COMPLETED | NCT07216313 |
| Placebo | Other | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| TVB-3567 | Other | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| Resmetirom | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT07216313 |
| TVB-3567 | DRUG | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| denifanstat | DRUG | Phase PHASE3 | MASLD | WITHDRAWN | NCT06692283 |
| Denifanstat | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT07216313 |
| TVB-2640 - 50 mg | DRUG | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05835180 |
| Enzalutamide | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05743621 |
| [14C]-TVB-2640 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05657834 |
| Placebo | DRUG | Phase PHASE1 | Acne | RECRUITING | NCT06989840 |
| TVB-2640 75 mg (US) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| Placebo (China) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 50 mg (China) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| Placebo (US) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 50 mg (US) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| TVB-2640 25 mg (US) | DRUG | Phase PHASE2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | COMPLETED | NCT03938246 |
| 3-V Bioscience-2640 | DRUG | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02948569 |
| TVB-2640 | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05743621 |